• 1
    Fosfomycin and derivatives by E. Bergogne-Berezin in antimicrobial agents. Bryskier A, ed. Washington, DC: ASM press, chapter 37 page 972.
  • 2
    Rousson N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506515.
  • 3
    Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul 2010; 44: 311321.
  • 4
    Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29: 127142.
  • 5
    Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 4350.
  • 6
    Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009; 34: 111120.
  • 7
    Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009; 18: 921944.
  • 8
    Bergogne-Berezin E, Muller-Serieys C, Joly-Guillou ML, Dronne N. Trometamol-fosfomycin (Monuril). Bioavailability and food-drug interactions. Eur Urol 1987; 13 (suppl): 6468.
  • 9
    Muller-Serieys C, Bergogne-Berezin E, Joly-Guillou ML. La fosfomycin-trometamol(Monuril): pharmacocinetique et interaction aliment-medicament. Pathol Biol 1987; 35: 753767.
  • 10
    Naber KG, Thyroff-Friesinger U. Fosfomycin-trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection 1990; 18 (suppl): S70S76.
  • 11
    Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364386.
  • 12
    Kanimoto Y, Greenwood D. Comparison of the response of Escherichia coli to fosfomycin and fosmidomycin. Eur J Clin Microbiol 1987; 6: 386391.
  • 13
    Greenwood D, Jones A, Eley A. Factors influencing the activity of the trometamol salt of fosfomycin. Eur J Clin Microbiol 1986; 5: 2934.
  • 14
    Shrestha NK, Tomford JW. Fosfomycin: a review. Infect Dis Clin Pract 2001; 10: 255260.
  • 15
    Kashanian J, Hakimian P, Blute M Jr et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102: 16341637.
  • 16
    Mazzulli T, Skulnick M, Small G et al. Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. Can J Infect Dis 2001; 12: 289292.
  • 17
    Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 3: CD001534.
  • 18
    Oteo J, Bautista V, Lara N et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL) -producing Escherichia coli. J Antimicrob Chemother 2010; 65: 24592463.
  • 19
    Naber GK, Schaeffer AJ, Heyns CF et al. Urogenital infections. Ed. 2010. European Association of Urology. – International Consultation on Urological Diseases.
  • 20
    Falagas ME, Vouloumanou EK, Togias AG et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 18621877.
  • 21
    de Cueto M, Hernandez JR, Lopez-Cerero L et al. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 2006; 24: 613616.
  • 22
    Wagenlehner FM, Schmiemann G, Hoyme U et al. National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients. Urologe A 2011; 50: 153169.
  • 23
    UpToDate: Fosfomycin Drug Information. 2011. Available at: (last accessed 12 June 2011).